CL2021001830A1 - Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa - Google Patents

Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa

Info

Publication number
CL2021001830A1
CL2021001830A1 CL2021001830A CL2021001830A CL2021001830A1 CL 2021001830 A1 CL2021001830 A1 CL 2021001830A1 CL 2021001830 A CL2021001830 A CL 2021001830A CL 2021001830 A CL2021001830 A CL 2021001830A CL 2021001830 A1 CL2021001830 A1 CL 2021001830A1
Authority
CL
Chile
Prior art keywords
treatment
hidradenitis suppurativa
lta4h
lta4h inhibitors
inhibitors
Prior art date
Application number
CL2021001830A
Other languages
English (en)
Inventor
Christian Loesche
Carlos Penno
Till Roehn
Grazyna Wieczorek
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2021001830A1 publication Critical patent/CL2021001830A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Abstract

La presente divulgación se relaciona con métodos para el tratamiento de la Hidradenitis Supurativa utilizando un inhibidor de LTA4H. También se divulgan en la presente inhibidores de LTA4H, para el tratamiento de pacientes con Hidradenitis Supurativa, así como también medicamentos, regímenes de dosificación, formulaciones farmacéuticas, combinaciones, formas de dosificación, y kits para utilizar en los usos y métodos divulgados.
CL2021001830A 2019-01-11 2021-07-08 Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa CL2021001830A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19151459 2019-01-11
US201962896923P 2019-09-06 2019-09-06

Publications (1)

Publication Number Publication Date
CL2021001830A1 true CL2021001830A1 (es) 2022-04-01

Family

ID=69177186

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001830A CL2021001830A1 (es) 2019-01-11 2021-07-08 Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa

Country Status (13)

Country Link
US (1) US20220117949A1 (es)
EP (1) EP3908279A1 (es)
JP (1) JP7222102B2 (es)
KR (1) KR102630669B1 (es)
CN (1) CN113260364A (es)
AU (1) AU2020207638B2 (es)
BR (1) BR112021013377A2 (es)
CA (1) CA3124924A1 (es)
CL (1) CL2021001830A1 (es)
IL (1) IL284307A (es)
MX (1) MX2021008303A (es)
TW (1) TWI828839B (es)
WO (1) WO2020144604A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
RU2686101C2 (ru) 2013-03-12 2019-04-24 Селтакссис, Инк. Способы ингибирования лейкотриен- а4-гидролазы
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
SI3083564T1 (sl) * 2013-12-20 2018-10-30 Novartis Ag Derivati heteroarilbutanojske kisline kot inhibitorji LTA4H
ES2916582T3 (es) 2015-11-26 2022-07-01 Novartis Ag Derivados de diaminopiridina
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
UY37412A (es) 2016-09-23 2018-04-30 Novartis Ag Compuestos de indazol para uso en lesiones de tendones y/o ligamentos
WO2018107158A1 (en) * 2016-12-09 2018-06-14 Celtaxsys, Inc. Monamine and monoamine derivatives as inhibitors of leukotriene a4 hydrolase
AU2017371362A1 (en) * 2016-12-09 2019-07-25 Celltaxis, Llc Pendant amines and derivatives as inhibitors of leukotriene A4 hydrolase

Also Published As

Publication number Publication date
BR112021013377A2 (pt) 2021-09-14
KR102630669B1 (ko) 2024-01-30
JP7222102B2 (ja) 2023-02-14
JP2022516995A (ja) 2022-03-03
CN113260364A (zh) 2021-08-13
MX2021008303A (es) 2021-10-13
TW202042804A (zh) 2020-12-01
IL284307A (en) 2021-08-31
KR20210113278A (ko) 2021-09-15
AU2020207638A1 (en) 2021-07-15
TWI828839B (zh) 2024-01-11
CA3124924A1 (en) 2020-07-16
EP3908279A1 (en) 2021-11-17
US20220117949A1 (en) 2022-04-21
AU2020207638B2 (en) 2023-04-13
WO2020144604A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
DOP2022000096A (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton
CL2020000075A1 (es) Carboxamidas como moduladores de los canales de sodio.
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
BR112018068565A2 (pt) combinações de inibidores de lsd1 para uso no tratamento de tumores sólidos
CO2018013747A2 (es) Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
UY36371A (es) Compuestos de indolcarboxamida inhibidores de quinasas tipo btk y tipo tec
UY32919A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
ECSP109934A (es) Compuesto - 946
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
CL2017001001A1 (es) Derivados de carbazaol
CL2020000220A1 (es) Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial.
CO2021015793A2 (es) Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33
DOP2017000146A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
UY35455A (es) Inhibidores tripeptidicos de la epoxicetona proteasa
CL2019003572A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
CO2019010559A2 (es) Composiciones y compuestos terapéuticos y métodos para utilizarlos
CL2021003034A1 (es) Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton
UY33790A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k e inhibidor de mek.
CO2022008817A2 (es) Macrociclos para uso en el tratamiento de enfermedades
CL2021002521A1 (es) Compuestos heteocíclicos y sus usos.
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton